BeOne Medicines (ONC) Gains Barclays Overweight Rating Ahead of Key 2025 Data Readouts [Yahoo! Finance]
BeOne Medicines Ltd. - American Depositary Shares (ONC)
Company Research
Source: Yahoo! Finance
of BeOne Medicines Ltd. (NASDAQ:ONC), rating it Overweight and setting a price target of $385 on the company's shares. The firm cited two anticipated “value-inflecting pivotal data readouts” that might propel the oncology company's growth. The first projected catalyst is data on BeOne's BTK inhibitor in first-line mantle cell lymphoma, which is due in the latter half of 2025. Barclays also mentioned that data in first-line gastroesophageal cancer for the company's PD1 inhibitor with anti-HER2 mixture will come in the fourth quarter of 2025. Another significant driver for BeOne Medicines Ltd. (NASDAQ:ONC), according to Barclays, is the significance of topline pivotal data for zanidatamab, with or without tislelizumab, in first-line gastroesophageal adenocarcinoma. BeOne Medicines Ltd. (NASDAQ:ONC) is a global biotechnology company that specializes in oncology medicines, particularly for blood cancers and solid tumors. While we acknowledge the potential of ONC as an investment,
Show less
Read more
Impact Snapshot
Event Time:
ONC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ONC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ONC alerts
High impacting BeOne Medicines Ltd. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ONC
News
- U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell LymphomaBusiness Wire
- BeOne Medicines (NASDAQ:ONC) was given a new $400.00 price target on by analysts at Truist Financial Corporation.MarketBeat
- BeOne Medicines (NASDAQ:ONC) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.MarketBeat
- BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025Business Wire
- BeOne Medicines (NASDAQ:ONC) had its price target raised by analysts at Royal Bank Of Canada from $395.00 to $408.00. They now have an "outperform" rating on the stock.MarketBeat
ONC
Earnings
- 11/6/25 - Beat
ONC
Sec Filings
- 12/1/25 - Form 4
- 11/19/25 - Form 4
- 11/14/25 - Form 4
- ONC's page on the SEC website